

Mesenchymal Stem Cell Homing to Advanced and Metastatic Prostate Cancer

Rosaline Habib

February 2018

Primary Supervisor: Dr Catherine Gorrie

Co-supervisors: Dr Eileen McGowan and Dr Jerran Santos.



A thesis submitted in fulfilment of the requirements for the degree of Doctor
of Philosophy, School of Life Sciences at the University of Technology Sydney

Certificate of original authorship

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as part of the collaborative doctoral degree and/or fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Signature of Student: Production Note:
Signature removed prior to publication.

Date: 15/02/2018

Acknowledgments

The long and arduous process that is a PhD has helped me to realise and appreciate all the love and support I have in my life. I am eternally grateful to all these people.

Firstly, I would like to acknowledge my sole supervisor for most of this PhD candidature, Dr Rosetta Martinello-Wilks. Thank you for your invaluable intellectual and resource contributions to this PhD project and for the many late nights spent together helping with experiments. I would like to thank the new supervisory team of Dr Cathy Gorrie, Dr Jerran Santos, and Dr Eileen McGowan, who without much notice took on the responsibility of supervising my PhD. To Cathy for taking charge of my PhD and adopting me into her lab group. To Jerran for his vital knowledge of MSCs and help with experiments. And finally, to Eileen for being there with me from the start even when she was not a supervisor. This included help with experiments and with writing, but also general advice over coffee/hot chocolate. I am also grateful to Professor Mike Ford for helping to resolve some issues with my candidature, including, but not limited to the allocation of funds for the completion of experimental work, Dr Nham Tran for help with PCR and RNA isolation, and to Dr Ann Simpson, who may have not been a supervisor on paper, but who helped me nonetheless to edit my thesis.

To the technical staff at UTS; Mike Johnson and Kun Xiao for their help with flow cytometry, Mercedes for helping me out with sourcing reagents and new lab space during what was a difficult final year, and Fiona and Lal from the Ernst facility for helping with animal work. .

I would like to acknowledge all my friends for their support. To the uni crew: Pam, Rob, Sam, Pete, Marty, Eunji, Elliot, Dario, Dilan, and Divya, thank you for all help in the lab, and for all

iii

the great times together spent playing games, eating too much food, and talking about the most random and strange things. Special mentions to my closest friends Divya, Eunji and Pam for all the sweet treats (Divya), long chats, advice, and emotional support. Thank you also to my girls from high school, Pam (again), Alvina, Vanessa, Jasmine, and Lorizah, for all your prayers, words of encouragement, and for the fun nights spent together laughing and being silly.

I am so grateful to my family, my siblings Allen, Nicole, and Christina, and in particular my parents, Antoun and Saada, for their unconditional love and unwavering support through times of heightened stress and anxiety. I am also grateful to my other family members, especially my cousin Mary.

Finally, I would like to acknowledge my boyfriend Kyan Woodpower. Thank you for drawing a couple of excellent figures for this thesis and for technical support with putting the final thesis together. But mostly thank you for being there with me to share those devastating lows and wonderful highs.

Table of Contents

Certificate of original authorship.....	i
Acknowledgments.....	ii
List of Figures	x
List of Tables	xiii
Abbreviations.....	xiv
Abstract.....	xix
1. General introduction.....	1
1.1 Prostate cancer	1
1.1.1 Diagnosis of PCa	2
1.1.2 Prostate cancer progression and treatment.....	4
1.1.2.1 Treatment of low risk PCa: PSA of ≤ 10 ng/mL, Gleason score of ≤ 6 , and stage T1c to T2a tumours	4
1.1.2.2 Treatment of intermediate risk PCa: PSA 10-20 ng/mL, Gleason score 7 and T2b-T2c.....	6
1.1.2.3 Treatment of high risk PCa: PSA >20 ng/mL, Gleason score 8–10 and T3–T4 tumours.....	6
1.1.2.4 Treatment of advanced and metastatic PCa.....	6
1.2 Alternative treatment strategies for advanced and metastatic PCa	8
1.2.2 Gene therapy for PCa treatment	8
1.2.2.1 Immunomodulatory approaches	10
1.2.2.2 Tumour suppressor genes.....	11
1.2.2.3 Gene directed enzyme prodrug therapy (GDEPT)	12
1.2.3 Cell immunotherapy for PCa.....	14
1.2.3.1 Haematopoietic stem cell transplantations.....	14
1.2.3.2 Indirect immunotherapy.....	15
1.2.3.3 Direct immunotherapy.....	18
1.3 Mesenchymal stem cells in the treatment of PCa	19
1.3.1 Defining mesenchymal stem cells.....	20
1.3.2 MSCs in gene therapy protocols for cancer	22
1.3.3 Effect of MSCs on tumour growth and development.....	23
1.3.4 Pre-clinical studies	24
1.3.4.1 Delivery of antitumorigenic cytokines	24
1.3.4.2 Delivery of prodrug-converting enzymes	25
1.3.4.3 Delivery of oncolytic viruses	28

1.4 Homing and the tumour microenvironment	29
1.4.1 Proposed mechanism of homing	29
1.4.1.1 Rolling	30
1.4.1.2 Firm adhesion	31
1.4.1.3 Transmigration.....	32
1.4.1.4 The role of chemokines and growth factors in homing.....	38
1.4.2 Inflammation and PCa.....	40
1.4.2.1 PCa microenvironment	41
1.4.2.1.1 Growth factors	42
1.4.2.1.2 Chemokines	45
1.4.3 Enhancing tumour tropism	47
Osteogenesis imperfecta	49
1.4.4 Importance of understanding the signals required for homing of BMSCs to PCa ..	50
1.4.5 Project significance	51
2. A preclinical model for monitoring therapeutic BMSC tumour migration to lung pseudometastases	52
2.1 Introduction	52
2.1.1 Preliminary data.....	56
2.1.1.1 BMSCs	56
2.1.1.2 BMSC vector constructs	56
2.1.1.3 Nucleofection of BMSCs.....	58
2.1.1.4 RM1-tracking cells.....	59
2.1.1.5 Bioluminescent reporter genes	60
2.1.2 Chapter aims	61
2.2 Methods.....	63
2.2.1 General cell culture techniques	63
2.2.1.1 Nucleofected BMSC culture	63
2.2.1.2 RM1-tracking culture	64
2.2.1.3 Cell storage	64
2.2.1.4 Cell counts.....	65
2.2.2 In vitro characterisation of bioluminescent signals	65
2.2.2.1 Timecourse for signal delay	66
2.2.2.2 Correlation of signal strength to cell number.....	66
2.2.2.3 Cross reactivity of BLI substrates	67

2.2.3 Animal breeding and care	67
2.2.4 Tail vein (IV) injections	68
2.2.5 Detection and quantitation of BMSCs in vivo and ex vivo	69
2.2.6. Detection and quantitation of RM1-tracking cells in vivo and ex vivo	71
2.2.7 Tracking of BMSC-Fcy:Fur to PCa lung pseudometastases (12 days)	74
2.2.8 Persistence of the D-Luc signal in vivo	75
2.2.9 Tracking of BMSC migration to PCa lung pseudometastases (30 hours)	76
2.2.10 Efficacy of BMSC-Fcy:Fur delivered GDEPT on PCa lung pseudometastases	77
2.2.11 Survival in PCa bearing B6-Albino mice treated with therapeutic BMSC	79
2.12 Statistical analysis	80
2.3 Results	81
2.3.1 BMSC and RM1 BLI signals decrease over time	81
2.3.2 BMSC and RM1 BLI signals directly correlate to cell number and do not cross react	81
2.3.3 BMSC-Fcy:Fur do not persist long-term in tumour bearing mice	87
2.3.4 BMSC bioluminescent signal decays in 2 hours	87
2.3.5 BMSCs show preferential persistence in the lungs of tumour bearing mice over a short time frame	90
2.3.6 BMSC delivered GDEPT reduces tumour burden in mice with RM1 Lung pseudometastases	95
2.3.7 BMSC delivered GDEPT marginally improves survival of mice with RM1 lung pseudometastases	98
2.4 Discussion	101
3. Isolation and characterisation of bone marrow-derived mesenchymal stem cells	107
3.1 Introduction	107
3.2 Methods	111
3.2.1 Isolation of unsorted bone marrow (BM)-derived cells (UBMC)	111
3.2.1.1 Excision of the hind limb	111
3.2.1.2 Flushing of the BM	111
3.2.1.3 Culturing of UBMC	112
3.2.1.4 Fluorescence activated cell sorting (FACS) of UBMC	112
3.2.2 BMSC culture	114
3.2.3 Cell surface marker characterisation of UBMCs and BMSCs	114
3.2.4 Growth (proliferation) assays	117
3.2.5 Clonogenicity assays	117

3.2.6 Differentiation assays	118
3.2.6.1 Chondrogenesis	118
3.2.6.2 Adipogenesis	118
3.2.6.3 Osteogenesis assay	120
3.2.7 In vitro migratory potential of the enriched BMSC population	120
3.2.7.1 RM1 cell culture	121
3.2.7.1 Culture of RM1 cells for conditioned medium (CM).....	121
3.2.7.2 Acclimatising BMSCs for Transwell migration assays	121
3.2.6.3 In vitro Transwell migration assays.....	121
3.2.8 Statistical analysis	123
3.3 Results.....	124
3.3.1 FACS sorting of BMSCs from the UBMC population.	124
3.3.2 Cell surface marker and morphological characterisation of UBMCs and BMSCs .	124
3.3.3 Comparative analysis of BMSC and UBMC proliferation (Trypan blue assay)	128
3.3.4 Colony forming potential of enriched BMSCs compared to UBMCs	128
3.3.5 BMSCs exhibit trilineage differentiation.....	132
3.3.6 Osteogenic differentiation analysis: comparison of BMSCs and UMSCs.....	132
3.3.7 Adipogenic differentiation analysis: comparison of BMSCs and UBMCs	132
3.3.8 Expression of CD90.2 and CD34 on the surface of BMSCs with increasing passage	137
3.3.9 In vitro migratory potential of the enriched BMSC population	138
3.4 Discussion.....	139
4. Identification of the distinct signals responsible for BMSC migration to PCa.	143
4.1 Introduction	143
4.2 Methods.....	145
4.2.1 Comparison of migration to conditioned medium (CM) and medium only (MO)	145
4.2.2 Optimisation of Transwell migration assays	145
4.2.2 Effect of CM on proliferation of BMSCs.....	147
4.2.3 Effect of proteinase K (PK) treatment on BMSC migration.....	147
4.2.3.1 Optimisation of PK concentration.....	147
4.2.3.2 Migration towards PK treated CM	148
4.2.4 Pertussis toxin treatment of BMSC.....	148
4.2.5 Profiling of differentially expressed genes in BMSCs exposed to CM	148
4.2.5.1 Exposing BMSCs to CM	148

4.2.5.2 RNA extraction from BMSCs	149
4.2.5.3 Assessment of RNA quality and concentration.....	150
4.2.5.5 Microarray gene expression profiling	150
4.2.5.7 Validation of target genes.....	151
4.2.6 Profiling of cytokines secreted by RM1 prostate cancer cells	152
4.2.6.1 Making MO and CM for cytokine arrays	152
4.2.6.2 Cytokine array	153
4.2.7 Effect of chemokine receptor inhibitors on BMSC migration.....	153
4.2.8 Overexpression of CXCR2 and CCR2 in BMSC-Fcy:Fur	154
4.2.8.1 Confirmation of vector identity	154
4.2.8.2 Nucleofection.....	155
4.2.8.3 Migration of nucleofected BMSC-Fcy:Fur to RM1	155
4.2.9 Statistical analysis	155
4.3 Results.....	157
4.3.1 BMSC migrate more efficiently towards RM1 CM compared to MO	157
4.3.2 A significant increase in migration to CM and MO is seen at 6-8 hours and this is not due to increased proliferation in CM	157
4.3.3. BMSCs migrate to CM in response to soluble proteins	160
4.3.4 Migration to CM is mediated by chemokines.....	160
4.3.5 Profiling of differentially expressed genes in BMSCs exposed to CM	163
4.3.5.1 Exposure of BMSCs to CM upregulates genes involved in migration	163
4.3.5.2 Candidate genes were expressed greater than 2-fold in BMSCs exposed to CM	163
4.3.6 RM1 prostate cancer cells secrete an array of growth factors and chemokines..	168
4.3.7 Migration to CM is facilitated by specific chemokine receptors	171
4.3.8 Overexpression of CCR2 an CXCR2 improves BMSC-Fcy:Fur migration to RM1 CM	172
4.4 Discussion.....	175
5. General discussion	182
5.1 Exploring the therapeutic potential of MSCs for the treatment of cancer.....	182
5.1.1 MSCs in clinical trials.....	182
5.1.2 Weaponised BMSCs as safe cancer therapies	184
5.1.2.1 Enriching for MSCs for Pre-clinical research.....	184
5.1.2.2 Dose, delivery, and timing of BMSC delivered GDEPT.....	184

5.1.2.3 BMSC delivered GDEPT is a safe and effective alternative to current cancer therapeutics	185
5.1.2.4 Understanding BMSC homing to improve homing to experimental PCa metastases	186
5.2 Limitations of the study	187
5.3 Recommendations for future work	188
5.3.1 Pre-clinical model.....	188
5.3.1.1 Use of a syngeneic mouse model	188
5.3.1.2 Selection of a source of MSCs.....	188
5.3.1.3 Enriching for MSCs from mice.....	188
5.3.1.4 Cancer model	189
5.3.2 BMSC homing to PCa	190
5.3.2.1 Exploring mechanisms behind homing further.....	190
5.3.2.2 Altering BMSCs to target and destroy metastatic PCa	190
5.4 Concluding remarks	193
6. Appendix	194
7. References	208

List of Figures

Figure 1.1 3D schematic of prostate gland depicting the structure of the prostate (central zone not shown).	1
Figure 1.2 Gleason's pattern scale.....	3
27	
Figure 1.3 5-Fluorouracil metabolism.....	27
Figure 1.4a Proposed mechanism of the mesenchymal stem cell extravasation cascade.	34
Figure 1.4b Capture and rolling	35
Figure 1.4c Firm adhesion.....	36
Figure 1.4d Transmigration.....	37
Figure 2.1 Gene directed prodrug therapy.	54
Figure 2.2 BMSC vector constructs.	57
Figure 2.3 BMSC nucleofection and creation of BMSC clones.....	59
60	
Figure 2.4 RM1 vector constructs.	60
Figure 2.5 Chemical reactions catalysed by luciferase enzymes	61
Figure 2.6 Plate set up for timecourse of BLI substrates	66
Figure 2.7 Plate set up for cross reactivity of BLI substrates	67
Figure 2.8 Detection and quantitation of BMSC-Fcy:Fur <i>in vivo</i>	70
Figure 2.9 Detection and quantitation of RM1-tracking cells <i>in vivo</i> and <i>ex vivo</i>	72
Figure 2.10 Diagram showing the methodology to track BMSC-Fcy:Fur to RM1-tracking lung pseudometastases in a long-term study.....	74
Figure 2.11 Diagram showing the methodology to establish the persistence of the D-LUC signal <i>in vivo</i>	75
77	
Figure 2.12 Diagram showing the methodology to track BMSC-Fcy:Fur to RM1-tracking lung pseudometastases in a short-term study.	77
Figure 2.13 Diagram showing the methodology for efficacy of BMSC delivered GDEPT on RM1-tracking lung pseudometastases.....	79
Figure 2.14 <i>In vitro</i> BMSC-tracking cell fl characteristics and D-LUC substrate signal strength.	83
83	
Figure 2.15 <i>In vitro</i> RM1- tracking cell fl characteristics and CLZ substrate signal strength. ..	84
Figure 2.16 <i>In vitro</i> cross-reactivity of D-LUC in vitro.	85

Fig 2.17 <i>In vitro</i> cross-reactivity of CLZ in vitro.	86
Figure 2.18 Preliminary long-term study tracking BMSC-Fcy:Fur to lung pseudometastases.	88
Figure 2.19 <i>In vivo</i> D-luciferin time-course.	89
Figure 2.20a Short-term <i>in vivo</i> tracking of BMSC-LacZ to the lungs of B6-Albino mice bearing RM1-tracking pseudometastases.	91
Figure 2.20b Quantitation of tumour burden using BLI at experiment endpoint	92
Figure 2.21a Short-term <i>in vivo</i> tracking therapeutic BMSC-Fcy:Fur to the lungs of B6-Albino mice bearing RM1-tracking pseudometastases.	93
Figure 2.21b Quantitation of tumour burden using BLI at experiment endpoint	94
96	
Figure 2.22 Therapeutic BMSC-Fcy:Fur imaging in the efficacy study.	96
Figure 2.23 Impact of BMSC-Fcy:Fur delivered GDEPT on RM1-tracking lung pseudometastases.	97
Figure 2.24 Therapeutic BMSC-Fcy:Fur imaging in the survival study.	99
2.25 Impact of BMSC delivered GDEPT on mouse survival.	100
Figure 3.1. Grading scheme for the semiquantitative analysis of adipogenesis.	119
Figure 3.2 Transwell migration assay.	122
Figure 3.3 Fluorescence-activated cell sorting (FACS) isolation of mouse bone marrow-derived mesenchymal stem cells (BMSCs).	125
Figure 3.4 Phenotypic and morphological analysis of UBMCs and BMSCs with positive and negative BMSC cell surface markers.	127
130	
Figure 3.5 Comparative analysis of growth (proliferation) curves for BMSC and UBMC by haemocytometer cell counts.	130
Figure 3.6 Comparative clonogenicity assay analysis between BMSCs and UBMCs.	131
Figure 3.7 BMSCs differentiate into adipocytes, chondrocytes, and osteocytes.	134
Figure 3.8 Osteogenic differentiation of BMSCs and UBMC.	135
Figure 3.9 Adipogenic differentiation of BMSCs and UBMCs	136
Figure 3.10 Analysis of CD34 and CD90.2 expression on mid-passage and late passage BMSCs.	137
Figure 3.11 Migration potential of BMSC towards condition media across the different passages.	138
Figure 4.1 Transwell migration assay.	146

Figure 4.2 pUNO1-CCR2 and pUNO1-CXCR2 vector constructs showing EcoRI restriction sites	
156	
158	
Figure 4.3 BMSC migration to RM1 prostate cancer CM.....	158
Figure 4.4 Optimisation of incubation time for migration assays.	159
Figure 4.5 Effect of proteinase K treatment on BMSC migration to CM.	161
162	
Figure 4.6 Effect of pertussis toxin (PTX) treatment on BMSC migration to CM.....	162
Figure 4.7 Differentially expressed genes in BMSCs exposed for 8 hrs to CM.	164
Figure 4.8 Gene ontology analysis of over-expressed genes in BMSCs exposed to CM.....	165
Figure 4.9 qPCR validation of target genes from the Affymetrix Mouse Gene 1.0 ST microarrays	166
Figure 4.10 Change in the expression of chemokine and growth factor receptors in BMSCs exposed to CM over time.....	167
Figure 4.11a Proteome Profiler Mouse XL Cytokine Array.	169
Figure 4.11b Proteome Profiler Mouse XL Cytokine Array of MO and murine RM1 serum free CM.	170
Figure 4.12 Effect of pertussis toxin (PTX) treatment on BMSC migration to CM.....	171
Figure 4.13 Confirmatory restriction digests of pUNO1-CCR2 and pUNO1-CXCR2.....	173
Figure 4.14 Migration of BMSC-Fcy:Fur/CXCR2 and BMSC-Fcy:Fur/CXCR2 to RM1 CM	174
Figure 4.15 Schematic depicting the proposed mechanism of homing towards PCa	181
Figure 5.1 Schematic overview of proposed strategies to improve homing of mesenchymal stem cells (MSCs) to tumour sites	192

List of Tables

Table 1.1 MSC-based delivery of therapeutic agents in pre-clinical development	29
Table 1.2 Chemoattractants implicated in the migration of MSCs	40
Table 1.3 Engraftment levels of intravenously administered MSCs in tissue injury models and therapeutic outcome	49
Table 1.4 Receptors and ligands implicated in the migration of MSCs to tumours	51
Table 2.1 Parental BMSC and stable gene expression clone characteristics	58
Table 2.2 Optimal BLI parameters for BMSC firefly luciferase (fl) and RM1-tracking renilla luciferase (rl)	73
Table 2.3 Final RM1-tracking and/or BMSC-Fcy:Fur cell concentration for tracking study.....	76
Table 2.4 Final RM1-tracking and/or BMSC-Fcy:Fur cell concentration for efficacy study	78
Table 2.5 Final RM1-tracking and/or BMSC-Fcy:Fur cell concentration for survival study	80
Table 3.1 List of BD Pharmingen sourced antibodies used to phenotypically characterize BMSCs and UBMCs	116
Table 4.1 Taqman assays for validation of candidate genes	152
Table 4.2 Chemokine receptor inhibitors	154
Table 5.1 Active clinical trials utilising MSCs for the treatment of human disease	183
Table 6.1 Gene therapy strategies in clinical development for prostate cancer	194
Table 6.2 Cellular immunotherapies in clinical development for the treatment of castrate resistant prostate cancer	196
Table 6.3 Semi-quantitative analysis of cytokines in RM1 CM detected in the Proteome Profiler Mouse XL Cytokine Array	200
Table 6.4 Gene list comprising targets with statistically significant fold changes of ± 1.9 from the microarray	204

Abbreviations

AAT	Androgen ablation therapy
ADT	Androgen deprivation therapy
Adv	Adenovirus
AFMS	Anterior fibromuscular stroma
α -MEM	alpha-Minimum Essential Medium
ANOVA	Analysis of variance
APC	Antigen presenting cells
AR	Androgen receptor
BFGF	Basic fibroblast growth factor
bFGF receptor	Basic fibroblast growth factor receptor
BM	Bone marrow
BMSC	Bone marrow-derived mesenchymal stem cells
BPH	Benign prostatic hyperplasia
CAR	Chimeric antigen receptor
CC	C-C motif
CCR	C-C motif receptor
CCD	Charge-coupled device
CD	Cytosine deaminase
CD:UPRT/Fcy:Fur	Cytosine deaminase uracil phosphoribosyl transferase
CEA	Carcinoembryonic antigen
CLZ	Coelenterazine
CM	Conditioned medium
CMV	Cytomegalovirus
CrAD	Conditionally replicating oncolytic Adv
CRPC	Castration-resistant PCa

xv	
CT	Threshold cycle
CTL	Cytotoxic T-lymphocyte
CXC	C-X-C motif
CXCR	C-X-C motif receptor
D-Luc	D-Luciferin
DMEM	Dulbecco's Modified Eagle's medium
D-PBS	Dulbecco's-Phosphate-Buffered Saline
DRE	Digital rectal examination
EBRT	External beam radiation therapy
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
ELISA	Enzyme-Linked Immunosorbent Assay
FACS	Fluorescence-activated cell sorting
FAK	Focal adhesion kinase
FC	Fluorocytosine
FCS	Foetal calf serum
FDA	Food and Drug Administration
Fl	Firefly luciferase
FdUDP	Fluorodeoxyuridine diphosphate
FdUMP	Fluorodeoxyuridine monophosphate
FdUTP	Fluorodeoxyuridine triphosphate
FGF	Fibroblast growth factor
FU	Fluorouracil
FUMP	fluorouridine monophosphate
GDEPT	Gene directed enzyme prodrug therapy
GFP	Green fluorescent protein
GITR	Glucocorticoid induced tumour necrosis factor receptor

xvi	
GMP	Good manufacturing practice
GRO	Growth-regulated oncogene
GVHD	Graft failure and graft-versus-host disease
GVT	Graft-versus-tumour
HBSS	Hank's Balanced Salt Solution
HCELL	hematopoietic cell E-selectin/L-selectin ligand
HGF	Human growth factor
HGPIN	High-grade prostatic intraepithelial neoplasia
HLA	Human Leukocyte Antigen
HPF	High Powered Field of View
HSC	Haematopoietic stem cells
HSCT	HSC transplantations
HTLV	Human T-cell Leukaemia Virus
HUVEC	Human umbilical vein endothelial cells
IA	Intraarterial
IC	Intracorporeal
ICAM-1	Intracellular adhesion molecule-1
IFN	Interferon
IGF	Interleukin growth factor
IGFR	Interleukin growth factor
IL	Interleukin
IM	Intramyocardial
IP	Intraperitoneal
IRES	Internal ribosome entry sequence
IRMT	Intensity modulated radiotherapy
ISCT	International Society for Cellular Therapy
IT	Intratumoral

xvii	
IV	Intravenously
IVC	Individual ventilated cage
IVIS	<i>In vivo</i> Imaging System
LacZ	β -galactosidase
LFA-1	lymphocyte function-associated antigen 1
LPAM-1	Integrin $\alpha_4 \beta_7$
MAC-1	Macrophage-1 antigen
MAdCAM-1	Mucosal vascular addressin cell adhesion molecule 1
mCRPC	Metastatic castrate-resistant prostate cancer
MHC	Major Histocompatibility Complex
MES-SDS	2-[N-morpholino]ethanesulfonic acid-Sodium dodecyl sulfate polyacrylamide
MO	Medium only
MRI	Magnetic resonance imaging
MSC	Mesenchymal stem cells
N.S	Not significant
NCCN	National comprehensive cancer network
NDV	Newcastle disease virus
NK	Natural killer
PAP	Prostate acid phosphatase
PBMC	Peripheral blood mononuclear cell
PBSC	Peripheral blood stem cell
PCa	Prostate cancer
PDGF	Platelet-derived growth factor
PET	Positron emission topography
PIN	Prostatic intraepithelial neoplasia
PNP	Purine nucleoside phosphorylase

xviii

PSA	Prostate specific antigen
P/S, glu	Penicillin/streptomycin, glutamine
PSGL1	P-selectin glycoprotein ligand 1
PSMA	Prostate specific membrane antigen
PZ	Peripheral zone
REIC	Reduced expression in immortalized cells
RI	Renilla luciferase
ROI	Regions of interest
RR	Ribonucleotide reductase
RT	Room temperature
SC	Subcutaneous
SGE	Super gene expression
sLex	sialyl Lewis X
SPECT	Single-photon emission computed tomography
TAA	Tumour-associated antigens
TBE	Tris/Brate/Ethylenediaminetetraacetic
TCR	T cell receptor
TK	Thymidine kinase
TRAIL	Tumour necrosis factor-related apoptosis-inducing ligand
TZ	Transition zone
UBMC	Unsorted bone marrow cells
UCMSC	Umbilical cord mesenchymal stem cell
VCAM	Vascular cell adhesion molecule
VEGF	Vascular endothelial growth factor
VLA	Very late antigen

Abstract

Prostate cancer (PCa) is the most common cancer affecting men worldwide. Current treatment strategies to combat advanced and metastatic disease are ineffective and this has created a need to explore novel therapies, such as cell and gene therapies. A promising strategy involves capitalising on the innate ability of bone marrow-derived mesenchymal stem cells (BMSCs) to home to sites of cancer and release a genetic payload. BMSCs have the added benefit of being immune evasive, which is a major problem for other cell and gene therapy protocols.

BMSCs used in this study had been previously stably nucleofected to express a cell tracking reporter gene firefly luciferase (fl) and the yeast fusion suicide gene cytosine deaminase and uracil phosphoribosyltransferase (BMSC-Fcy:Fur). RM1 murine PCa cells were gene modified with the cell tracking reporter gene renilla luciferase (rl). An immune intact B6 albino mouse model was developed to investigate BMSC-Fcy:Fur homing to RM1 lung pseudometastases, and therapeutic effect. Using bioluminescence imaging (BLI) it was discovered that BMSC-Fcy:Fur showed greater persistence in the lungs of mice with RM1 tumours at 3 hours post-injection compared to their cancer free counterparts, however the BMSCs did not persist for longer than 24 hours in the lungs likely because of their advanced passage. By delivering prodrug when BMSC-Fcy:Fur were largely present in the lungs, a significant decrease lung RM1 colonies and a 25% improvement in survival was achieved. Importantly, BMSC-Fcy:Fur treatment was associated with no adverse events and did not promote PCa growth, confirming their safety for allogenic use in the treatment of PCa.

xx

Previous findings have led to investigations into why BMSCs are attracted to PCa and how to best capitalise BMSC-PCa tropism for the development of novel therapies for metastatic PCa. It was anticipated that a greater understanding of the molecular events governing BMSC tropism for cancer may permit improved therapeutic BMSC targeting to metastatic PCa. Towards this aim, I isolated and characterised a subpopulation of BMSCs from B6 albino mouse BM. Cells were sorted from early passage following dual colour staining with antibodies against a stem cell antigen-1 (Sca-1) and a haematopoietic marker (CD45). Specifically, when compared to unsorted BM cells (UBMCs), the subpopulation showed: typical BMSC

phenotype: Sca-1⁺, CD44⁺, CD90⁺, CD106⁺, CD31⁻, CD34⁻ and CD45; enhanced adipogenic ability; similar osteogenic ability; and similar colony formation ability. Subsequently, these BMSCs were used to understand the signals mediating migration towards PCa. BMSC migration to RM1 derived conditioned medium (CM) was assessed using Transwell migration assays. These assays revealed that migration was due to soluble chemokines. Cytokine arrays and genome wide microarrays identified candidate chemokine receptors CCR2, CXCR2, CCR1, and CCR5 as potential mediators of BMSC migration towards RM1 CM. Inhibition of individual chemokine receptors led to a reduction in migration of BMSCs to RM1 CM, however not to level observed with pertussis toxin alone suggesting multiple or other chemoattractant receptors (chemokine receptors or growth factor receptors) may be involved in migration. Importantly, it was found that overexpression of CCR2 and CXCR2 on the surface of BMSC-Fcy:Fur significantly improved their migration to RM1 PCa CM.

In this thesis, I have demonstrated that systemic delivery of allogenic BMSCs followed by GDPET activation at a time when BMSCs are most localised to the tumour, is a safe and efficacious method to combat late stage PCa. Moreover, I showed for the first time that BMSCs can be enriched from B6 albino mice using Sca-1 and CD45 cell sorting. Lastly, I showed that BMSCs migration is facilitated by various chemokine receptors and overexpression of CCR2

xxi

and CXCR2 promotes migration to RM1 CM. These findings provide new insights into the signals mediating migration to PCa and may be exploited in future to improve on migration of BMSCs to PCa.